SNHG15 functions as a tumor suppressor in thyroid cancer

Liu, Yongcun; Li, Junli; Li, Feng; Li, Meng; Shao, Yuan; Wu, Liping

doi:10.1002/jcb.27899

Cited by 26 publications

(44 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Growing evidences show lncRNAs exert important roles in the development and progression of various cancers, including HCC. [17][18][19] For example, lncRNA LINC00461 is upregulated in HCC and promotes cancer cell proliferation and invasion through miR-149-5p/ LRIG2 pathway. 20 LncRNA PVT1 regulates HCC progression via promoting autophagy.…”

Section: Discussionmentioning

confidence: 99%

LncRNA ASB16-AS1 Promotes Growth And Invasion Of Hepatocellular Carcinoma Through Regulating miR-1827/FZD4 Axis And Activating Wnt/β-Catenin Pathway

Yao¹,

You²,

Zhou³

et al. 2019

CMAR

View full text Add to dashboard Cite

These authors contributed equally to this work Background: To date, although several long noncoding RNAs (lncRNAs) are reported to regulate hepatocellular carcinoma (HCC) development, their relationship still remains elusive. ASB16-AS1 is a poorly researched novel lncRNA. We aimed to investigate its function in HCC progression. Methods: qRT-PCR and in situ hybridization (ISH) were used to analyze ASB16-AS1 expression in HCC tissues. CCK8, Edu incorporation and colony formation were used to determine cell proliferation. Transwell assay was used to examine migration and invasion. Luciferase reporter assay was used to analyze the interactions among ASB16-AS1, miR-1827 and FZD4. Results: Bioinformatics analysis identified ASB16-AS1 was overexpressed in HCC tissues, which was further validated by qRT-PCR and in situ hybridization (ISH). Besides, ASB16-AS1 was demonstrated to be a potential indicator for HCC prognosis. Functional studies showed ASB16-AS1 knockdown attenuated proliferation, migration and invasion of HCC cells. Mechanistically, ASB16-AS1 directly interacted with miR-1827 and promoted FZD4 expression by sponging miR-1827. Overexpressed FZD4 eventually activated Wnt/β-catenin pathway and contributed to HCC progression. Conclusion: Our work is the first to identify ASB16-AS1 as an oncogene that enhances HCC progression by modulating miR-1827/FZD4/Wnt/β-catenin pathways.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA ASB16-AS1 Promotes Growth And Invasion Of Hepatocellular Carcinoma Through Regulating miR-1827/FZD4 Axis And Activating Wnt/β-Catenin Pathway

Yao¹,

You²,

Zhou³

et al. 2019

CMAR

View full text Add to dashboard Cite

show abstract

“…Compared with non‐cancerous TC samples, the expression level of SNHG15 was lower in TC tissue samples . Low expression level of SNHG15 was identified to closely associate with age, pathology classification, clinical stage, tumour size and distant metastasis in TC patients . However, current evidences mainly focus the overexpression of SNHG15 in most cancers.…”

Section: Expression Pattern Functions and Clinical Potentials Of Snhmentioning

confidence: 97%

“…Expression profile data of various cancers from The Cancer Genome Atlas (TCGA) data set showed that only TC specimens displayed lower levels of SNHG15 expression . Liu et al validated the expression status of SNHG15 in a cohort of 40 paired TC tissues and adjacent non‐tumour samples using qRT‐PCR assay . Compared with non‐cancerous TC samples, the expression level of SNHG15 was lower in TC tissue samples .…”

Section: Expression Pattern Functions and Clinical Potentials Of Snhmentioning

confidence: 99%

“…SNHG15 is reported to significantly upregulated in most types of cancers and serves as an oncogenic regulator in cancer development and progression, including CRC, GC, HCC and PC . However, SNHG15 can also act as a tumour suppressor in TC tissues compared with normal tissues . The diversity of these studies can be partly explained by tumour heterogeneity, different gene expression background, different sources of tumour samples, as well as limited numbers of specimens.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

LncRNA SNHG15: A new budding star in human cancers

Shuai

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

Objectives Long non‐coding RNAs (lncRNAs) represent an important group of non‐coding RNAs (ncRNAs) with more than 200 nucleotides in length that are transcribed from the so‐called genomic “dark matter.” Mounting evidence has shown that lncRNAs have manifested a paramount function in the pathophysiology of human diseases, especially in the pathogenesis and progression of cancers. Despite the exponential growth in lncRNA publications, our understanding of regulatory mechanism of lncRNAs is still limited, and a lot of controversies remain in the current lncRNA knowledge.The purpose of this article is to explore the clinical significance and molecular mechanism of SNHG15 in tumors. Materials & Methods We have systematically searched the Pubmed, Web of Science, Embase and Cochrane databases. We provide an overview of current evidence concerning the functional role, mechanistic models and clinical utilities of SNHG15 in human cancers in this review. Results Small nucleolar RNA host gene 15 (SNHG15), a novel lncRNA, is identified as a key regulator in tumorigenesis and progression of various human cancers, including colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PC) and hepatocellular carcinoma (HCC). Dysregulation of SNHG15 has been revealed to be dramatically correlated with advanced clinicopathological factors and predicts poor prognosis, suggesting its potential clinical value as a promising biomarker and therapeutic target for cancer patients. Conclusions LncRNA SNHG15 may serve as a prospective and novel biomarker for molecular diagnosis and therapeutics in patients with cancer.

show abstract

“…Additionally, the research of Morvarid Saeinasab et al well elucidated that SNHG15 could facilitate cell proliferation, invasion and drug resistance in colorectal cancer functioned as a bifunctional MYC-regulated noncoding locus encoding a lncRNA by interacting with AIF. Similarly, Jiang et al demonstrated that in colon cancer, SNHG15 promoted tumor progression via stabilizing transcription factor Slug [18,19].However, as a tumor suppressor, only Liu et al reported that SNHG15 was downregulated in thyroid cancer tissue samples and cells and its inhibited expression positively enhanced cell proliferation, migration, invasion in vitro [20].…”

mentioning

confidence: 99%

Upregulation of LncRNA SNHG15 indicates an unfavourable prognosis and clinical features of patients in multiple malignancies: a meta-analysis and bioinformatics

Chen¹,

Feng²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: A snoRNA host gene named SNHG15 which produces a short half-lived lncRNA has been reported to be dysregulated in multiple cancers and correlated with tumor progression in published researches recently. So this meta-analysis was performed to evaluate the generalized prognostic effect of SNHG15 on malignancies because of the discrepant data amongst different studies.Methods: Four public databases were utilized for identifying eligible studies. The association between prognostic indicators and clinical features were extracted and pooled for estimation of the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs). Publication bias and the stability of pooled results were measured by Begg’s test, Egger’s test and sensitivity analysis respectively. Additionally, Online database based on The Cancer Genome Atlas (TCGA) was screened and further validate our results.Results: Totally eleven studies including 1087 patients were ultimately enrolled in our paper. Promoted SNHG15 expression was associted with worse OS and DFS.Moreover, increased SNHG15 expression suggested advanced TNM stage and LNM but not correlated with age, gender and tumor size. No publication bias and instability of result were observed. SNHG15 was significantly upregulated in seven cancers and elevated expression of SNHG15 indicated shorter OS and DFS in five malignancies according to the validation using GEPIA (Gene Expression Profiling Interactive Analysis).Conclusions: Promoted expression of lncRNA SNHG15 was markedly related to worse prognosis and clinical features, suggesting that SNHG15 might serve as a novel factor in various cancers.

show abstract

SNHG15 functions as a tumor suppressor in thyroid cancer

Cited by 26 publications

References 19 publications

<p>LncRNA ASB16-AS1 Promotes Growth And Invasion Of Hepatocellular Carcinoma Through Regulating miR-1827/FZD4 Axis And Activating Wnt/β-Catenin Pathway</p>

<p>LncRNA ASB16-AS1 Promotes Growth And Invasion Of Hepatocellular Carcinoma Through Regulating miR-1827/FZD4 Axis And Activating Wnt/β-Catenin Pathway</p>

LncRNA SNHG15: A new budding star in human cancers

Upregulation of LncRNA SNHG15 indicates an unfavourable prognosis and clinical features of patients in multiple malignancies: a meta-analysis and bioinformatics

Contact Info

Product

Resources

About